BCA
MRVI icon

Berman Capital Advisors’s Maravai LifeSciences MRVI Stock Holding History

Berman Capital Advisors’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$1K Buy
+27
New +$1.32K ﹤0.01% 1911

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Berman Capital Advisors's MRVI Position: Q3 2021 in Review

Berman Capital Advisors opened a new position in Maravai LifeSciences (MRVI) in Q3 2021: 27 shares worth $1K. The stake represents ﹤0.01% of the portfolio and ranks #1911 among its holdings.

228 funds tracked by Wall St. Rank hold MRVI as of Q3 2021.

  • Berman Capital Advisors held 27 shares of Maravai LifeSciences worth $1K as of Q3 2021.
  • Maravai LifeSciences was a new Berman Capital Advisors position in Q3 2021.
  • Maravai LifeSciences made up ﹤0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #1911 holding.
  • 228 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.